Imbruvica 欧州連合 - フィンランド語 - EMA (European Medicines Agency)

imbruvica

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Adrenalin 0.1 mg/ml injektioneste, liuos フィンランド - フィンランド語 - Fimea (Suomen lääkevirasto)

adrenalin 0.1 mg/ml injektioneste, liuos

takeda oy - adrenaline tartrate - injektioneste, liuos - 0.1 mg/ml - adrenaliini

Sinemet 25 mg / 100 mg tabletti フィンランド - フィンランド語 - Fimea (Suomen lääkevirasto)

sinemet 25 mg / 100 mg tabletti

n.v. organon - carbidopa, levodopa - tabletti - 25 mg / 100 mg - levodopa ja dekarboksylaasin estäjä

Kardopal 100 mg / 25 mg tabletti フィンランド - フィンランド語 - Fimea (Suomen lääkevirasto)

kardopal 100 mg / 25 mg tabletti

orion corporation - carbidopa, levodopa - tabletti - 100 mg / 25 mg - levodopa ja dekarboksylaasin estäjä

Sinemet 12.5 mg / 50 mg tabletti フィンランド - フィンランド語 - Fimea (Suomen lääkevirasto)

sinemet 12.5 mg / 50 mg tabletti

n.v. organon - carbidopa, levodopa - tabletti - 12.5 mg / 50 mg - levodopa ja dekarboksylaasin estäjä